Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease

Cardiology Clinics

Volumn 33, Issue 2, 2015, Pages 309-323

  Brinton, Eliot A ^a  

^a Utah Foundation for Biomedical Research   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Hypertriglyceridemia; Triglycerides

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C; APOLIPOPROTEIN E; CHOLESTEROL; CHYLOMICRON; DOCOSAHEXAENOIC ACID; FENOFIBRATE; ICOSAPENTAENOIC ACID; LIPOPROTEIN; LIPOPROTEIN LIPASE; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ATHEROGENESIS; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; GENERAL PRACTITIONER; HEREDITY; HOMOZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA; HYPERTRIGLYCERIDEMIA; LIPOLYSIS; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM; BLOOD; COMPLICATION; DISEASE MANAGEMENT;

ATHEROSCLEROSIS; DISEASE MANAGEMENT; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; TRIGLYCERIDES;

EID: 84928814571     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2015.02.007     Document Type: Review

References (79)

1. Maki K.C., Bays H.E., Dicklin M.R. Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence. JClin Lipidol 2012, 6:413-426.
2. Ford E.S., Li C., Zhao G., et al. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med 2009, 169:572-578.
3. Christian J.B., Bourgeois N., Snipes R., et al. Prevalence of severe (500 to 2,000 mg/dl) hypertriglyceridemia in United States adults. Am J Cardiol 2011, 107:891-897.
4. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-e209.
5. Hegele R.A., Ginsberg H.N., Chapman M.J., et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2014, 2:655-666.
6. Miller M., Stone N.J., Ballantyne C., et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011, 123:2292-2333.
7. Kersten S. Physiological regulation of lipoprotein lipase. Biochim Biophys Acta 2014, 1841:919-933.
8. Glueck C.J., Fallat R., Buncher C.R., et al. Familial combined hyperlipoproteinemia: studies in 91 adults and 95 children from 33 kindreds. Metabolism 1973, 23:1403-1428.
9. Glueck C.J., Tsang R., Fallat R., et al. Familial hypertriglyceridemia: studies in 130 children and 45 siblings of 36 index cases. Metabolism 1973, 22:1287-1309.
10. Hopkins P.N., Wu L.L., Hunt S.C., et al. Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. JAm Coll Cardiol 2005, 45:1003-1012.
11. Hopkins P.N., Nanjee M.N., Wu L.L., et al. Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case-control study. Atherosclerosis 2009, 207:559-566.
12. Hopkins P.N., Brinton E.A., Nanjee M.N. Hyperlipoproteinemia type 3: the forgotten phenotype. Curr Atheroscler Rep 2014, 16:440.
13. Sarwar N., Sandhu M.S., Ricketts S.L., et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634-1639.
14. Austin M.A., Hokanson J.E., Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998, 81:7B-12B.
15. Sarwar N., Danesh J., Eiriksdottir G., et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation 2007, 115:450-458.
16. Liu J., Zeng F.F., Liu Z.M., et al. Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies. Lipids Health Dis 2013, 12:159.
17. Sacks F.M., Alaupovic P., Moye L.A., et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000, 102:1886-1892.
18. Miller M., Cannon C.P., Murphy S.A., et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. JAm Coll Cardiol 2008, 51:724-730.
19. Drexel H., Aczel S., Marte T., et al. Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis. Atherosclerosis 2010, 208:484-489.
20. Wang L., Gill R., Pedersen T.L., et al. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. JLipid Res 2009, 50:204-213.
21. Goldberg I.J., Eckel R.H., McPherson R. Triglycerides and heart disease: still a hypothesis?. Arterioscler Thromb Vasc Biol 2011, 31:1716-1725.
22. Ginsberg H.N. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002, 106:2137-2142.
23. Schlaich M.P., Grassi G., Lambert G.W., et al. European Society of Hypertension Working Group on Obesity Obesity-induced hypertension and target organ damage: current knowledge and future directions. JHypertens 2009, 27:207-211.
24. Liu L., Wen T., Zheng X.Y., et al. Remnant-like particles accelerate endothelial progenitor cells senescence and induce cellular dysfunction via an oxidative mechanism. Atherosclerosis 2009, 202:405-414.
25. Mahley R.W., Innerarity T.L., Rall S.C., et al. Lipoproteins of special significance in atherosclerosis. Insights provided by studies of type III hyperlipoproteinemia. Ann N Y Acad Sci 1985, 454:209-221.
26. Ferreira A.C., Peter A.A., Mendez A.J., et al. Postprandial hypertriglyceridemia increases circulating levels of endothelial cell microparticles. Circulation 2004, 110:3599-3603.
27. Norata G.D., Grigore L., Raselli S., et al. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis 2007, 193:321-327.
28. Shin H.K., Kim Y.K., Kim K.Y., et al. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 2004, 109:1022-1028.
29. Tanimura K., Nakajima Y., Nagao M., et al. Association of serum apolipoprotein B48 level with the presence of carotid plaque in type 2 diabetes mellitus. Diabetes Res Clin Pract 2008, 81:338-344.
30. Langsted A., Freiberg J.J., Tybjaerg-Hansen A., et al. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. JIntern Med 2011, 270:65-75.
31. Zheng C., Azcutia V., Aikawa E., et al. Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion. Eur Heart J 2013, 34:615-624.
32. Ginsberg H.N., Brown W.V. Apolipoprotein CIII: 42 years old and even more interesting. Arterioscler Thromb Vasc Biol 2011, 31:471-473.
33. Caron S., Verrijken A., Mertens I., et al. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2011, 31:513-519.
34. Ginsberg H.N. Insulin resistance and cardiovascular disease. JClin Invest 2000, 106:453-458.
35. Lamarche B., Tchernof A., Moorjani S., et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation 1997, 95:69-75.
36. St-Pierre A.C., Ruel I.L., Cantin B., et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 2001, 104:2295-2299.
37. Hirano T., Ito Y., Koba S., et al. Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol 2004, 24:558-563.
38. Rizzo M., Kotur-Stevuljevic J., Berneis K., et al. Atherogenic dyslipidemia and oxidative stress: a new look. Transl Res 2009, 153:217-223.
39. Packard C., Caslake M., Shepherd J. The role of small, dense low density lipoprotein (LDL): a new look. Int J Cardiol 2000, 74(Suppl 1):S17-S22.
40. Berneis K.K., Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity. JLipid Res 2002, 43:1363-1379.
41. Anber V., Griffin B.A., McConnell M., et al. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 1996, 124:261-271.
42. Goulinet S., Chapman M.J. Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis. Arterioscler Thromb Vasc Biol 1997, 17:786-796.
43. Nigon F., Lesnik P., Rouis M., et al. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. JLipid Res 1991, 32:1741-1753.
44. Younis N., Charlton-Menys V., Sharma R., et al. Glycation of LDL in non-diabetic people: Small dense LDL is preferentially glycated both invivo and invitro. Atherosclerosis 2009, 202:162-168.
45. Zheng C., Khoo C., Furtado J., et al. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation 2010, 121:1722-1734.
46. Brinton E.A., Eisenberg S., Breslow J.L. Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. JClin Invest 1991, 87:536-544.
47. Brinton E.A., Eisenberg S., Breslow J.L. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 1994, 14:707-720.
48. Rizzo M., Spinas G.A., Cesur M., et al. Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naive patients with early rheumatoid arthritis. Atherosclerosis 2009, 207:502-506.
49. Do R., Willer C.J., Schmidt E.M., et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 2013, 45:1345-1352.
50. Jørgensen A.B., Frikke-Schmidt R., Nordestgaard B.G., et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. NEngl J Med 2014, 371:32-41.
51. Chapman M. Fibrates: therapeutic review. Br J Diabetes Vasc Dis 2006, 6:11-20.
52. Kamanna V.S., Kashyap M.L. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?. Am J Cardiol 2007, 100:S53-61.
53. McKenney J.M., Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy 2007, 27:715-728.
54. Ginsberg H.N., Elam M.B., Lovato L.C., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. NEngl J Med 2010, 362:1563-1574.
55. Ginsberg H.N. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial: what we learn from subgroup analyses. Diabetes Care 2011, 34(Suppl 2):S107-S108.
56. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
57. Scott R., O'Brien R., Fulcher G., et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009, 32:493-498.
58. Sacks F.M., Carey V.J., Fruchart J.C. Combination lipid therapy in type 2 diabetes. NEngl J Med 2010, 363:692-694. [author reply: 694-5].
59. Risk, Prevention Study Collaborative Group, Roncaglioni M.C., Tombesi M., et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. NEngl J Med 2013, 368:1800-1808.
60. ORIGIN Trial Investigators, Bosch J., Gerstein H.C., et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. NEngl J Med 2012, 367:309-318.
61. Writing Group for the AREDS2 Research Group, Bonds D.E., Harrington M., et al. Effect of long-chain omega-3 fatty acids and lutein+ zeaxanthin supplements on cardiovascular outcomes: results of the Age-related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA Intern Med 2014, 174:763-771.
62. Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
63. Cannon C. Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) 2014, AHA Scientific Sessions, Chicago.
64. Saito Y., Yokoyama M., Origasa H., et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008, 200:135-140.
65. Bruckert E., Labreuche J., Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010, 210:353-361.
66. Boden W.E., Probstfield J.L., Anderson T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. NEngl J Med 2011, 365:2255-2267.
67. Guyton J.R., Slee A.E., Anderson T., et al. Relationship of lipoproteins to cardiovascular events: The AIM-HIGH trial (atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides and impact on global health outcomes). JAm Coll Cardiol 2013, 62:1580-1584.
68. Group TCDPWR Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360-381.
69. Canner P.L., Furberg C.D., McGovern M.E. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the coronary drug project). Am J Cardiol 2006, 97:477-479.
70. Landray M.J., Haynes R., Hopewell J.C., et al. Effects of extended-release niacin with laropiprant in high-risk patients. NEngl J Med 2014, 371:203-212. HPS2-THRIVE Collaborative Group.
71. Stone N.J., Robinson J.G., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129:S1-S45.
72. Reduction of Cardiovascular Events with EPA - Intervention Trial (REDUCE-IT). Available at: Accessed January 6, 2015. http://https://clinicaltrials.gov/ct2/show/NCT01492361?term=reduce-it%26rank=1.
73. Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh CardiovascularRiskPatienTswith Hypertriglyceridemia (STRENGTH). Available at: Accessed January 6, 2015. http://https://clinicaltrials.gov/ct2/show/NCT02104817?term=epanova%26rank=4.
74. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004, 110:227-239.
75. Gibbons G.H., Shurin S.B., Mensah G.A., et al. Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute. JAm Coll Cardiol 2013, 62:1396-1398.
76. Stone N., Robinson J., Lichtenstein, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013, 1-84.
77. Chapman M.J., Ginsberg H.N., Amarenco P., et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk ofcardiovascular disease: evidence and guidance for management. Eur Heart J 2011, 32:1345-1361.
78. Ishida T., Ohta M., Nakakuki M., et al. Distinct regulation of plasma LDL cholesterol by eicosapentaenoic acid and docosahexaenoic acid in high fat diet-fed hamsters: participation of cholesterol ester transfer protein and LDL receptor. Prostaglandins Leukot Essent Fatty Acids 2013, 88:281-288.
79. Wei M.Y., Jacobson T.A. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep 2011, 13:474-483.